Battle Brazil:
Defeating T2DM in the ASCVD Patient
Program Director
Peter Libby
Program Director
Raul Santos
The IAS has created a Brazilian focused education program consisting of series of pre-recorded video- based programs to comprehensively address the matter of managing patients with diabetes mellitus (DM) and ASCVD. The goal is to close knowledge and practice gaps, reduce clinician uncertainty, and demonstrate how the guidelines and evidence can be applied in a practical manner.
Covering the spectrum of topic areas governed by rigorous and evidence- based discussions of global experts, existing guidelines, and state of the art analysis, the series will illuminate method of action information for the major classes of therapeutics or discussion of the use of specific biomarkers, analysis of reports, and risk estimation tools. Also available with Portuguese subtitles.
Pre-Activity Information
This activity is designed for an audience of Global healthcare professionals, including endocrinologists, diabetologists, lipidologists, cardiologists, and primary care clinicians (PCPs).
A 4 part video series aimed at medical professionals to comprehensively address the matter of managing patients with diabetes mellitus (T2DM) and ASCVD.This video series, presented by world-renowned medical experts, is for endocrine, lipid and cardiology clinicians practicing in Brazil.
Video 1 discussion to include:
o Diabetes and the changing landscape of atherosclerosis
o Inflammation, insulin resistance and atherosclerosis
Video 2 discussion to include:
o Diabetes mellitus and cardiovascular disease
o Subclinical atherosclerosis and cardiovascular risk in prediabetes and diabetes atherosclerosis
Video 3A discussion to include:
o Atherogenic dyslipidemia, cardiovascular disease and diabetes
o Hypertension, kidney disease and cardiovascular disease in diabetes
o Glucose control for prevention of cardiovascular disease
Video 3B discussion to include:
o Impact of agonists of GLP-1 on atherosclerotic cardiovascular disease
o LDL-c reduction and prevention of CVD in pre-diabetes and diabetes
o Impact of SGLT2 inhibitors on heart failure and kidney endpoints
Video 4 is a discussion to wrap up the video series, with comments on the main key messages presented
The IAS is proud to present this esteemed global faculty. More information on each faculty member can be found by clicking on their names.
Rhanderson Cardoso
Dr. Cardoso declares no sources of funding and no relationships with commercial stakeholders in the healthcare sector.
Antonio Carlos Chagas
Dr. Chagas declares no sources of funding and no relationships with commercial stakeholders in the healthcare sector.
Alice Cheng
Dr. Cheng declares sources of funding and relationships with the following commercial stakeholders in the healthcare sector: Advisory board or speaking honoraria from: Abbott, Astra Zeneca, Bausch, Bayer, Boehringer Ingelheim, Dexcom, Eli Lilly, HLS Therapeutics, Insulet, Janssen, Medtronic, Novo Nordisk, Sanofi, Takeda.
Keith Ferdinand
Dr. Ferdinand declares sources of funding and relationships with the following commercial stakeholders in the healthcare sector: Consultant with Amgen, Novartis, Boehringer Ingelheim, Janssen, Pfizer.
Peter Libby
Dr. Libby makes the following disclosures: Grant/Research support: Novartis; Unpaid Consultant and/or unpaid steering or executive committee of: Clinical trials: Amgen, Esperion, Genentech, Kowa, Merck, Novartis, Pfizer, Sanofi-Aventis-Regeneron. Scientific Advisory Board: Amgen, Beren, Caristo, Cartesian, CSL, Behring, DalCor, Dewpoint, Kancera, Medimmune, Novartis, NovoNordisk, Olatec, PlaqueTec, Xbiotech. Board: Xbiotech.
Dr. Libby declines all personal compensation from pharma or device companies. Dr. Libby has a financial interest in Xbiotecj, a company developing therapeutic human antibodies. Dr. Libby’s interests were reviewed and are managed by Brigham and Women’s Hospital and Partners HealthCare in accordance with their conflict-of-interest policies.
Samia Mora
Dr. Mora makes the following disclosures: Consultant for Quest Diagnostics and Pfizer.
Aruna Pradhan
Dr. Pradhan declares that she receives industry support for the conduct of PROMINENT Study which is evaluating the role of triglyceride lowering with pemafibrate for cardiovascular risk reduction in T2D.
Paul Ridker
Dr. Ridker has sources of funding and relationships with the following commercial stakeholders in the healthcare sector: Consultant Fees/ Honoraria: Agepha, AstraZeneca, Boston Pharma, Civi Biopharma, Corvidia, Flame, Inc., IQVIA, Janssen Pharmaceuticals, Novartis, Novo Nordisk, Omeicos, Siranomics, Health Outlook. Research/Research Grants: Amarin, Kowa Pharmaceuticals, Novartis.
Viviane Rocha Giraldez
Dr. Rocha Giradez declares sources of funding and relationships with the following commercial stakeholders in the healthcare sector: Honoraria related to lectures and consulting from: Abbott, Amgen, Astra Zeneca, BIOLAB, Libbs, Novartis, Novo Nordisk.
Dr. Santos declares sources of funding and relationships with the following commercial stakeholders in the healthcare sector concerning consulting, speaker and or research activities from: Abbott, Aché, Amryt, Astra Zeneca, Amgen, EMS, Esperion, GETZ Pharma, Kowa, Libbs, Merck, MSD, Novo Nordisk, Pfizer, PTC Therapeutics, Roche, Sanofi.
Naveed Sattar
Dr. Sattar declares sources of funding and relationships with the following commercial stakeholders in the healthcare sector: Consulting for: Afimmune, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hanmi Pharmaceuticals, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, Sanofi. Grant support paid to his University from: AstraZeneca, Boehringer Ingelheim, Novartis, Roche Diagnostics.
Stephen Wiviott
Dr. Wiviott reports research grants from Amgen, AstraZeneca, Daiichi Sankyo, Eisai, Janssen, and Merck. He reports consulting fees from AstraZeneca, Boston Clinical Research Institute, Icon Clinical, Novo Nordisk. Spouse, Dr. Caroline Fox is an employee of Merck.
Kathleen Wyne
Dr. Wyne declares the following sources of funding are not related to the topic: Research funding to Ohio State University from Intercept Pharmaceuticals, Target NASH, Amryt Pharma, and Genentech, Inc.
IAS planners and reviewers disclosed no financial relationship.
The IAS is very grateful to Novo Nordisk for their support of this educational activity.